Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal

Prostate Cancer Webinars | PP-PF-ONC-GB-0413, February 2024

Oncology
BOPA 2021
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1299, February 2024
P3 Prostate Cancer Forum: Series Overview
NUBEQA®▼ (darolutamide) | Xofigo®▼ (radium-223 dichloride)
PP-NUB-GB-1318, February 2024
BAUS 2022: Navigating treatment decisions in nmCRPC patients
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1298, February 2024
BAUN 2022
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1314, February 2024
ASCO-GU 2023: The DEAR study in nmCRPC
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1296, February 2024
ASCO-GU 2023: ARASENS post-hoc analysis
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1297, February 2024
BAUS 2023: When and how to treat prostate cancer?
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1300, February 2024
Highlights from ASCO-GU and EAU
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1409, February 2024
The evolving nmCRPC treatment landscape
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1320, February 2024
SMC accepts darolutamide▼ in mHSPC
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1491, February 2024
BNMS 2022
Xofigo®▼ (radium-223 dichloride)
PP-NUB-GB-1301, February 2024
Real world evidence from the RALU study
Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0459, February 2024
P3 Prostate Cancer Forum: Session 4
NUBEQA®▼ (darolutamide) | Xofigo®▼ (radium-223 dichloride)
PP-NUB-GB-1489, February 2024
Radiology run mCRPC treatment clinic
Xofigo®▼ (radium-223 dichloride)
PP-NUB-GB-1308, February 2024
Evolving mCRPC treatment landscape in 2023
Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0505, February2024
BAUS 2023: The role of Urologists in the MDT
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1319, February 2024
0-0 of 0